Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.
Advanced genetic testing identifies treatable cancer drivers missed by standard tests, connecting patients with better-matched therapies.
BACKGROUND: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). The clinical relevance of CGP-identified new driver detection appears linked to standard targeted therapy availability and translation of actionable findings into matched therapy.
What the study was
- Study design
- Observational/unspecified
- Population
- cancer patients
- Sample size
- 2296
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Lung cancer (Amsterdam, Netherlands)
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Observational/unspecified (Journal Article) matched 'Precision oncology and genomic medicine'. Components — novelty:2/3, relevance:2/3, design:1/2, population:2/2. Confidence: medium. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.